about
Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study.Delayed Sputum Conversion in TB-HIV Co-Infected Patients with Low Isoniazid and Rifampicin Concentrations.High efavirenz serum concentrations in TB/HIV-coinfected Ugandan adults with a CYP2B6 516 TT genotype on anti-TB treatmentA comparative study of logistic regression based machine learning techniques for prediction of early virological suppression in antiretroviral initiating HIV patientsHIV-1 Drug Resistance Among Ugandan Adults Attending an Urban Out-Patient ClinicRetention of HIV infected pregnant and breastfeeding women on option B+ in Gomba District, Uganda: a retrospective cohort studyTen years of antiretroviral therapy: Incidences, patterns and risk factors of opportunistic infections in an urban Ugandan cohortResearch priorities to inform “Treat All” policy implementation for people living with HIV in sub-Saharan Africa: a consensus statement from the International epidemiology Databases to Evaluate AIDS (IeDEA)Incidence rate of sexually transmitted infections among HIV infected patients on long-term ART in an urban and a rural clinic in UgandaAn observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavirAcceptability, perceived reliability and challenges associated with distributing HIV self-test kits to young MSM in Uganda: a qualitative studyPsychosocial correlates of regular syphilis and HIV screening practices among female sex workers in Uganda: a cross-sectional surveyReasons for first line ART modification over the years during the ART scale up in UgandaVirological Outcome of Patients With HIV Drug Resistance Attending an Urban Outpatient Clinic in Uganda: A Need for Structured Adherence Counseling and Third-Line Treatment OptionsBending the Arc towards Equitable Partnerships in Global Health and Applied TrainingThe Influence of Pharmacogenetic Variants in HIV/Tuberculosis Coinfected Patients in Uganda in the SOUTH StudyAntiretroviral concentration measurements as an additional tool to manage virologic failure in resource limited settings: a case control studySustained positive impact on tuberculosis treatment outcomes of TB-HIV integrated care in UgandaIncreasing retention of HIV positive pregnant and breastfeeding mothers on option-b plus by upgrading and providing full time HIV services at a lower health facility in rural UgandaImplementing routine physical function screening among elderly HIV-positive patients in UgandaLonger-term effectiveness of protease-inhibitor-based second line antiretroviral therapy in four large sub-Saharan African clinicsLow Antituberculosis Drug Concentrations in HIV-Tuberculosis-Coinfected Adults with Low Body Weight: Is It Time To Update Dosing Guidelines?Evaluation of the Management of Patients with Detectable Viral Load after the Implementation of Routine Viral Load Monitoring in an Urban HIV Clinic in UgandaImportance of routine viral load monitoring: higher levels of resistance at ART failure in Uganda and Lesotho compared with Switzerland
P50
Q41996343-894A7A4E-A0DE-4161-BE5E-84DABF038534Q52669182-D9740CF9-71A3-49EC-980F-AD5D954959C4Q56909387-63B7F2CB-BFF9-4038-849C-AB36CF62C084Q56909671-3CFCBCE7-C0F2-42B9-BDD0-C46D97F0DC63Q56910439-C7D3C572-BC85-43A9-B053-4333C3E98A9CQ57790188-44CBF66A-6A1A-4121-8453-813E60B0A807Q58084945-F8C621FC-3077-48A1-ADDF-0DDBF8D63E21Q60915907-6E5D2EFD-C6D2-468F-96C5-D3C9922B5C60Q61446334-E2683E28-EDA3-42D2-A75A-93757CC3B5C2Q64054070-75D6CF81-89DD-4DB7-8AF8-BFB1B41123DDQ64094670-B9BACFAE-5282-4845-A256-014184894F2BQ90166231-E2AAA3E0-2D9E-45DC-AF84-2ADEDD2CD17FQ90615370-8BD05BFB-0655-49CB-AEF9-E2EE8D5C2F18Q90998937-4A3BD9E1-7925-458F-8BB2-865CD4EABD4CQ91369186-8AF2D0CA-B5FB-40BC-8FE3-E9ADCBAB136AQ91699232-6E9124E0-1689-4835-8284-130B13A1AF7CQ91763469-61943FC9-1743-4E1F-9CCD-9C464BC4A854Q91830337-AB35E436-6E16-43FA-9924-AF730764C127Q91894987-2D1E89C5-884F-4124-B367-09AFC3C2AFAFQ92052541-3EA28557-BA52-4AB9-9DDF-C4084BE04A86Q92229910-FE0396D6-CA39-4DB5-B70F-E5D12F85F45DQ92613648-280DDFBE-E00C-413D-9786-0A8CA2355699Q92620989-3EC61476-3E98-4AC5-A04B-E0DA25510A8EQ93370271-DD57D430-D279-43EE-8F97-782D245033FE
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Barbara Castelnuovo
@en
Barbara Castelnuovo
@nl
type
label
Barbara Castelnuovo
@en
Barbara Castelnuovo
@nl
prefLabel
Barbara Castelnuovo
@en
Barbara Castelnuovo
@nl
P31
P496
0000-0001-7756-5032